Drug intelligence / Profile preview

HLIM

Development stage: Phase 3
Lead developer: Sam-A Pharm
Modality: Small Molecules

Overview

HLIM is a drug developed by SamA Pharmaceutical Co., Ltd. It is currently undergoing Phase III clinical trials to assess its efficacy and safety for the symptomatic relief of cough and sputum in patients with acute upper respiratory tract infection or acute bronchitis.

Brand names: Hebron-L
Other names: HLIM

Targets

ADRB2 (β2)HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on HLIM.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HLIM.

Explore the full profile